Evolent Health (EVH) Earnings Date & Reports

Key Takeaways

• Evolent Health reported third-quarter 2026 revenue of $725.4 million, up 51.3% year over year, though the figure came in slightly below Wall Street consensus estimates.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was $34.3 million, down from $39.0 million a year earlier, with the adjusted EBITDA margin compressing to 4.7% from 8.1%.
• GAAP (generally accepted accounting principles) net loss narrowed to roughly $23.6 million, or $0.21 per share, from $26.9 million, or $0.24 per share, a year ago; adjusted earnings per share improved to $0.06 from $0.05.
• Performance Suite revenue nearly doubled to $564.3 million, while the medical expense ratio (MER) improved sequentially to 93.0% from 95.0% in the prior quarter.
• Management reaffirmed full-year 2026 revenue guidance of $2.6 billion to $2.7 billion and raised adjusted EBITDA guidance to $130 million to $135 million.
• For more details on Evolent Health's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated EVH pages on Tickeron.
• Looking for automated trade ideas? Explore Trending AI Robots to see AI-driven strategies currently in focus.

Earnings Context and Why It Matters

Evolent Health operates at the center of value-based specialty care, helping health plans manage complex populations in oncology, cardiology, and musculoskeletal care. Its third-quarter 2026 results arrive at a pivotal moment as the company pivots heavily toward risk-based Performance Suite contracts, which carry more medical claims exposure but offer larger revenue potential. Investors are closely watching whether rapid top-line growth can translate into sustainable profitability. Prior quarters showed strong revenue momentum alongside margin pressure and rising leverage, making this report a key test of management's ability to balance growth with disciplined cost control. The raised full-year EBITDA outlook signals confidence, even as a shrinking fee-based business and elevated medical expense ratio (MER) remain central concerns for the stock's valuation and investor sentiment.

Reported Results

For the quarter ended September 30, 2026, Evolent Health reported total revenue of $725.4 million, a 51.3% increase from $479.5 million in the prior-year period. Growth was driven overwhelmingly by the Performance Suite, where revenue nearly doubled to $564.3 million from $286.9 million a year ago, aided by a full quarter of Highmark revenue and the recognition of contractual adjustments. The average per member per month (PMPM) fee rose to $26.14 from $14.77.

Profitability metrics were mixed. Adjusted EBITDA declined 12.1% to $34.3 million from $39.0 million, pushing the adjusted EBITDA margin down to 4.7% from 8.1%. The medical expense ratio (MER) improved sequentially to 93.0% from 95.0% in the second quarter, reflecting favorable claims development. On a GAAP basis, net loss attributable to common shareholders narrowed to approximately $23.6 million, or $0.21 per share, from $26.9 million, or $0.24 per share. Adjusted earnings per share rose to $0.06 from $0.05 a year earlier.

Notably, the non-risk-based segments showed weakness: Specialty Technology & Services revenue fell to roughly $72.8 million from $93.3 million, while average unique members slipped to 39.8 million from 40.8 million, underscoring the shift toward higher-revenue, lower-margin risk contracts.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market more efficiently. It scans thousands of equities and exchange-traded funds using customizable criteria such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener surfaces trade ideas, trending stocks, breakout candidates, and emerging opportunities based on technical patterns, fundamentals, volatility, and AI-driven signals, reducing the time spent on manual research. For investors monitoring earnings-driven movers like Evolent Health, the AI Screener offers a practical way to identify comparable setups and market opportunities.

Market Reaction and Investor Sentiment

The third-quarter report produced a mixed read for investors. Strong revenue growth and a raised full-year adjusted EBITDA outlook provided positive signals, but margin compression, a declining fee-based business, and elevated leverage tempered enthusiasm. The company's shift toward risk-based Performance Suite contracts continues to weigh on profitability, with adjusted EBITDA falling year over year even as revenue surged more than 50%. Investors appear focused on whether the 220 basis point sequential improvement in the medical expense ratio marks the start of a durable trend. With roughly $148 million in unrestricted cash and net debt of approximately $776 million, balance-sheet strength remains a key area of scrutiny, as does the sustainability of margin recovery heading into 2027.

Forward Outlook and Key Factors to Monitor

Management reaffirmed full-year 2026 revenue guidance of $2.6 billion to $2.7 billion and raised its adjusted EBITDA outlook to $130 million to $135 million, up from a prior range of $120 million to $135 million. The company expects a sequential adjusted EBITDA increase of roughly $11 million to $16 million in the fourth quarter, driven by continued MER improvement.

Looking further ahead, Evolent outlined three tailwinds for 2027: contract maturation, including a full year of partnerships launched in 2026; incremental membership growth from new and expanded partnerships; and cost reductions tied to AI initiatives and an enterprise-wide cost review. These are partially offset by headwinds including Medicaid membership attrition and planned client attrition in Administrative Services.

Key factors to monitor include the trajectory of the medical expense ratio, the pace of Performance Suite contract launches, progress on debt reduction, and whether the company can convert its scale into stronger earnings and cash generation. Management has expressed confidence in a 2027 adjusted EBITDA midpoint of $150 million or higher, making execution on margin and cost initiatives a central watchpoint for investors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations